Trials / Completed
CompletedNCT05527964
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
The Influence of Specific Targeted Therapy on Subject and Family Quality of Life, Anxiety, Depression and Sleep Quality in Patients With Severe Refractory Atopic Dermatitis in the Czech Republic
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 146 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: * Change in disease activity after 16 and 24 weeks * Change in subject and family quality of life after 16 and 24 weeks * Change in sleep quality after 16 and 24 weeks * Change in anxiety after 16 and 24 weeks * Change in depression after 16 and 24 weeks * Safety and tolerability
Detailed description
28 weeks
Conditions
Timeline
- Start date
- 2022-12-30
- Primary completion
- 2025-06-16
- Completion
- 2025-06-16
- First posted
- 2022-09-06
- Last updated
- 2025-08-15
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT05527964. Inclusion in this directory is not an endorsement.